Brokerages Expect Encompass Health Co. (NYSE:EHC) Will Post Quarterly Sales of $1.21 Billion

Share on StockTwits

Wall Street brokerages predict that Encompass Health Co. (NYSE:EHC) will post $1.21 billion in sales for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Encompass Health’s earnings, with estimates ranging from $1.20 billion to $1.22 billion. Encompass Health reported sales of $1.18 billion in the same quarter last year, which indicates a positive year over year growth rate of 2.5%. The firm is scheduled to announce its next quarterly earnings results after the market closes on Tuesday, January 26th.

On average, analysts expect that Encompass Health will report full-year sales of $4.64 billion for the current year, with estimates ranging from $4.63 billion to $4.65 billion. For the next year, analysts anticipate that the firm will report sales of $5.06 billion, with estimates ranging from $4.96 billion to $5.16 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Encompass Health.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $0.78 EPS for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. Encompass Health had a return on equity of 15.52% and a net margin of 5.76%. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.18 billion.

A number of brokerages have commented on EHC. Barclays upgraded Encompass Health to an “overweight” rating and set a $96.00 price objective for the company in a research report on Monday, November 23rd. Raymond James lifted their price target on Encompass Health from $78.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, November 30th. Finally, Credit Suisse Group reduced their price target on Encompass Health from $89.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, November 2nd. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Encompass Health presently has a consensus rating of “Buy” and an average target price of $91.64.

Shares of NYSE EHC opened at $83.29 on Thursday. Encompass Health has a one year low of $48.01 and a one year high of $87.35. The firm has a market capitalization of $8.28 billion, a PE ratio of 31.19, a PEG ratio of 12.52 and a beta of 1.10. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 1.87. The business has a 50-day moving average price of $82.72 and a two-hundred day moving average price of $69.96.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Monday, January 4th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Thursday, December 31st. Encompass Health’s payout ratio is 28.64%.

Encompass Health Company Profile

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Featured Story: Why Net Income is Important to Investors

Get a free copy of the Zacks research report on Encompass Health (EHC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with's FREE daily email newsletter.